Drug Profile
Research programme: rare genetic disorder therapeutics - Actus Therapeutics
Alternative Names: Rare genetic diseases - ActusLatest Information Update: 28 Jan 2022
Price :
$50
*
At a glance
- Originator Duke University
- Developer Actus Therapeutics
- Class Antiepileptic drugs; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Epilepsy; Inborn genetic disorders